Patents by Inventor Jeremy Bastid

Jeremy Bastid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral suspension of temozolomide
    Patent number: 11730732
    Abstract: A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: August 22, 2023
    Assignees: Orphelia Pharma, Institut Gustave Roussy
    Inventors: Maxime Annereau, Jérémy Bastid, Hugues Bienayme, François Lemare, Mathieu Schmitt, Lionel Tortolano, Samuel Abbou
  • COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS
    Publication number: 20230045494
    Abstract: The present invention concerns the combination of CTLA4 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-CTLA4 therapies.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 9, 2023
    Inventors: Nathalie BONNEFOY, Jérémy BASTID, Armand BENSUSSAN
  • NOVEL IL-17B ANTIBODIES
    Publication number: 20220281967
    Abstract: The invention relates to novel IL-17B antagonist antibodies and their use in the diagnosis or treatment of IL-17B mediated diseases.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Inventors: Jérémy BASTID, Nathalie BONNEFOY, Armand BENSUSSAN, Gilles ALBERICI
  • COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS
    Publication number: 20220175815
    Abstract: The present invention concerns the combination of PD1 and IL-17B inhibitors, especially for the treatment of patients and diseases resistant to anti-PD1 therapies.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 9, 2022
    Inventors: Nathalie BONNEFOY, Jérémy BASTID
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20210261686
    Abstract: The present invention relates to a CD39 antagonist for use for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell.
    Type: Application
    Filed: December 28, 2020
    Publication date: August 26, 2021
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
  • ORAL SUSPENSION OF TEMOZOLOMIDE
    Publication number: 20200188390
    Abstract: The present invention concerns a pharmaceutical composition, advantageously a liquid suspension, comprising: a. temozolomide or a salt thereof; b. at least one agent controlling the solid state of temozolomide in suspension; c. a pharmaceutically acceptable liquid vehicle, advantageously water; d. optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 18, 2020
    Applicants: Orphelia Pharma, Institut Gustave Roussy
    Inventors: Maxime ANNEREAU, Jérémy BASTID, Hugues BIENAYME, François LEMARE, Mathieu SCHMITT, Lionel TORTOLANO
  • Antagonists of IL-17 isoforms and their uses
    Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • COMBINATIONS THERAPIES FOR THE TREATMENT OF CANCER
    Publication number: 20190151346
    Abstract: The present invention relates to combinations therapies for the treatment of cancer. In particular the present invention relates to a method for enhancing the potency of an HER inhibitor administered to a patient as part of a treatment regimen, the method comprising administering to the patient a pharmaceutically effective amount of an IL-17B or IL-17E inhibitor in combination with the HER inhibitor.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 23, 2019
    Inventors: Reem AL-DACCAK, Jérôme GIUSTINIANI, Jérémy BASTID, Armand BENSUSSAN, Yacine MERROUCHE, Christian GARBAR
  • CD39 VASCULAR ISOFORM TARGETING AGENTS
    Publication number: 20190153113
    Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 23, 2019
    Inventors: Jérémy BASTID, Laurent GAUTHIER, Carine PATUREL, Ivan PERROT, Alain ROUSSEL, Béatrice AMIGUES
  • ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES
    Publication number: 20180066051
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 8, 2018
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Antagonists of IL-17 isoforms and their uses
    Patent number: 9834601
    Abstract: The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: December 5, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • IL-17 ANTAGONIST ANTIBODIES
    Publication number: 20170233468
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 17, 2017
    Inventors: GILLES ALBERICI, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • IL-17 antagonist antibodies
    Patent number: 9676847
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 13, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • IL-17 ANTAGONIST ANTIBODIES
    Publication number: 20150104457
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Application
    Filed: June 25, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • ANTAGONISTS OF IL-17 ISOFORMS AND THEIR USES
    Publication number: 20150104456
    Abstract: The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Application
    Filed: June 11, 2013
    Publication date: April 16, 2015
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean- Francois Eliaou
  • Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
    Publication number: 20140023650
    Abstract: The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 23, 2014
    Applicants: INSTITUT MEDICAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, OREGA BIOTECH
    Inventors: Jérémy Bastid, Nathalie Bonnefoy, Agnès Doreau-Bastid, Jean-François Eliaou
  • ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
    Publication number: 20130273062
    Abstract: Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 17, 2013
    Applicant: OREGA BIOTECH
    Inventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
  • Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
    Publication number: 20110293629
    Abstract: The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17.
    Type: Application
    Filed: May 13, 2011
    Publication date: December 1, 2011
    Inventors: Jérémy BASTID, Nathalie BONNEFOY-BERARD, Agnés DOREAU-BASTID, Jean-François ELIAOU